Clinical trials: Type 2 Diabetes With Renal Manifestations
Diabetic Nephropathy
Effect of Pyridorin in Patients With Diabetic Nephropathy
The primary objective of the study is to evaluate the safety, tolerability and efficacy of Pyridorin (pyridoxamine dihydrochloride) up to 250 mg given orally twice daily in patients with diabetic kidney disease.
- Trial name
- NCT00320021
- Testing
- Pyridorin (pyridoxamine dihydrochloride)
- Volunteers
- 80 people
- Sponsor
- BioStratum
Type 2 Diabetes Mellitus With Diabetic Nephropathy
Safety and Efficacy of Oral GKT137831 in Patient With Type 2 Diabetes and Albuminuria
NADPH oxidase enzymes (NOX) have been implicated in the development of several diabetic complications including diabetic nephropathy. GKT137831 is the first in class NOX1/4 inhibitor.
- Trial name
- NCT02010242
- Testing
- GKT137831
- Where
- 48 sites in United States, Australia and 4 more
- Volunteers
- 136 people
- Sponsor
- Calliditas Therapeutics AB
Chronic Kidney Diseases, Diabetic Kidney Disease
Real World Evidence Clinical Utility Study of KidneyIntelX
The purpose of this study is to assess the impact of the KidneyIntelX assay utilized as part of the current standard of care on the management of patients seen in the primary care physician's office at Mount Sinai.
- Trial name
- NCT04802395
- Testing
- KidneyIntelX
- Where
- United States
- Volunteers
- 10,000 people
- Sponsor
- Renalytix AI, Inc.
Diabetic Kidney Disease
A Double-blind Study to Investigate Efficacy, Safety and Tolerability of BAY1142524 in Patients With Type II Diabetes and a Clinical Diagnosis of Diabetic Kidney Disease
The purpose of the trial is the analysis of safety and efficacy of the chymase inhibitor BAY1142524 at a dose of 25 mg BID in comparison to placebo using a 6 months treatment period in type II diabetic patients with a clinical…
- Trial name
- CADA DIA (NCT03412006)
- Testing
- Fulacimstat (BAY1142524)
- Where
- 27 sites in Bulgaria, Denmark and 5 more
- Volunteers
- 152 people
- Sponsor
- Bayer
Heart Failure, Chronic Kidney Disease
Efficacy, Safety and Tolerability of AZD9977 and Dapagliflozin in Participants With Heart Failure and Chronic Kidney Disease
The purpose of the study is to evaluate the efficacy and safety of AZD9977 in combination with dapagliflozin compared with dapagliflozin alone and to assess the dose-response relationship, dapagliflozin alone and 3 doses of…
- Trial name
- MIRACLE (NCT04595370)
- Testing
- AZD9977, Dapagliflozin
- Where
- 156 sites in United States, Belgium and 20 more
- Volunteers
- 153 people
- Sponsor
- AstraZeneca
Diabetic Nephropathy
Efficacy and Safety of Canagliflozin (TA-7284) in Patients With Diabetic Nephropathy
The purpose of this study is to evaluate the efficacy and safety of Canagliflozin (TA-7284) in Japanese patients with Diabetic Nephropathy, compared with placebo
- Trial name
- NCT03436693
- Testing
- Canagliflozin
- Where
- 26 sites in Japan
- Volunteers
- 308 people
- Sponsor
- Tanabe Pharma Corporation
IgA Nephropathy, Focal Segmental Glomerulosclerosis
Atrasentan in Patients With Proteinuric Glomerular Diseases
The AFFINITY Study is a phase 2, open-label, basket study to evaluate the efficacy and safety of atrasentan in patients with proteinuric glomerular disease who are at risk of progressive loss of renal function.
- Conditions
- IgA Nephropathy, Focal Segmental Glomerulosclerosis, Alport Syndrome, Diabetic Kidney Disease
- Trial name
- AFFINITY (NCT04573920)
- Testing
- Atrasentan
- Where
- 33 sites in United States, Australia and 4 more
- Volunteers
- 103 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Kidney Disease, Diabetic Nephropathy
A Prospective, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate Efficacy and Safety of Atrasentan, Including Thoracic Bioimpedance, in Type 2 Diabetic Subjects With Nephropathy
Prospective, Randomized, Double-Blind, Parallel Design, Placebo-Controlled Multicenter Study. The study objectives are to evaluate efficacy and safety, including thoracic bioimpedance, of once daily administration of atrasentan…
- Trial name
- NCT01399580
- Testing
- Atrasentan
- Where
- 28 sites in United States
- Volunteers
- 48 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Diabetic Kidney Disease
Phase 2 Study of TMX-049 in Subjects With Type 2 Diabetes and Albuminuria
The primary objective of this study is to assess the effect of 2 dose levels of TMX-049 on urinary albumin excretion in subjects with Type 2 diabetes and albuminuria (a urinary albumin-to-creatinine ratio (UACR) 200 to 3000 mg/g…
- Trial name
- NCT03449199
- Testing
- TMX-049
- Where
- 55 sites in United States
- Volunteers
- 130 people
- Sponsor
- Teijin America, Inc.
Diabetic Nephropathy
Efficacy and Safety Study of Probucol in Patients With Diabetic Nephropathy
This trial is randomized, placebo-controlled, double blind, double dummy, multi-centre trial. Screening period (4 week) Double blind treatment period (16 weeks)
- Trial name
- NCT01726816
- Testing
- Probucol 250mg/day, Probucol 500mg/day
- Where
- 16 sites in South Korea
- Volunteers
- 126 people
- Sponsor
- Korea Otsuka Pharmaceutical Co., Ltd.
Diabetic Nephropathy
Effect of Pyridorin in Patients With Diabetic Nephropathy
The primary objective of the study is to evaluate the safety and tolerability of Pyridorin (pyridoxamine dihydrochloride) 50 mg given orally twice daily in patients with diabetic kidney disease.
- Trial name
- NCT00320060
- Testing
- Pyridorin (pyridoxamine dihydrochloride)
- Volunteers
- 128 people
- Sponsor
- BioStratum
Diabetic Nephropathy
Open Label Tolerability and Safety Study of KRX-101 in Australia, New Zealand, and Hong Kong
The purpose of this study is to assess the tolerability and safety of KRX-101 in treating persistent microalbuminuria in type 2 diabetic patients who are also being treated with stable, maximum tolerated doses of either ACE…
- Trial name
- NCT00462202
- Testing
- sulodexide
- Where
- Australia
- Volunteers
- 200 people
- Sponsor
- Keryx Biopharmaceuticals
Diabetic Kidney Disease
Phase 2 Study of INV-202 in Patients With Diabetic Kidney Disease
The study is designed to assess the efficacy, safety, tolerability, and transformation within the human body of INV-202 investigational drug in the treatment of adult participants with a diagnosis of Diabetic Kidney Disease due…
- Trial name
- NCT05514548
- Testing
- INV-202
- Where
- 72 sites in United States, Canada and 5 more
- Volunteers
- 265 people
- Sponsor
- Inversago Pharma Inc.
Hypertension, Diabetic Nephropathies
A Prospective, Randomised, Double-blind, Double-dummy, Forced-titration, Multicentre, Parallel Group, One Year Treatment Trial to Compare Telmisartan (MICARDIS) 80 mg Versus Losartan (COZAAR) 100 mg, in Hypertensive Type 2 Diabetic Patients With Overt Nephropathy (AMADEO Study)
A number of blood pressure lowering drugs in the class known as angiotensin receptor blockers (ARB) have been shown to slow the decline in kidney function of patients with type 2 diabetes, high blood pressure, and kidney disease.
- Trial name
- NCT00168857
- Testing
- telmisartan, losartan
- Where
- 109 sites in United States, Argentina and 8 more
- Volunteers
- 860 people
- Sponsor
- Boehringer Ingelheim
Diabetic Kidney Disease
SER150 vs Placebo in Diabetic Kidney Disease
This study is to assess the efficacy and safety of SER150 administered for 24 weeks as a 15 mg twice a day BID dose (except on Day 168 15 mg QD) in participants with type 2 diabetes (T2D) and albuminuria in treatment with either…
- Trial name
- NCT04881123
- Testing
- SER150
- Where
- 12 sites in Australia, New Zealand
- Volunteers
- 20 people
- Sponsor
- Serodus AS
Diabetic Nephropathy, Type 2 Diabetes
Safety and Efficacy of Mesenchymal Precursor Cells in Diabetic Nephropathy
The study investigates the safety, tolerability and efficacy of a single intravenous infusion of two doses of mesenchymal precursor cells versus placebo in subjects with diabetic nephropathy and type 2 diabetes.
- Trial name
- NCT01843387
- Testing
- Mesenchymal Precursor Cells (MPCs)
- Where
- 2 sites in Australia
- Volunteers
- 30 people
- Sponsor
- Mesoblast, Ltd.
Diabetic Nephropathy
Study Of Diabetic Nephropathy With Atrasentan
The study objective was to evaluate the effect of atrasentan compared with placebo on time to doubling of serum creatinine (DBSC) or the onset of end-stage renal disease (ESRD) in participants with type 2 diabetes and nephropathy…
- Trial name
- SONAR (NCT01858532)
- Testing
- Atrasentan
- Volunteers
- 5,107 people
- Sponsor
- AbbVie
Diabetic Nephropathy
A Study to Evaluate Pharmacodynamics, Safety, Tolerability and Pharmacokinetics of MT-3995 in Type II Diabetic Nephropathy Subjects With Albuminuria and Moderately Decreased GFR
The purpose of this study is to evaluate pharmacodynamics, safety, tolerability and pharmacokinetics of MT-3995 in Type II Diabetic Nephropathy Subjects with Albuminuria and Moderately Decreased GFR
- Trial name
- NCT01756716
- Testing
- MT-3995 Low, MT-3995 High
- Where
- 50 sites in Bulgaria, Czechia and 4 more
- Volunteers
- 49 people
- Sponsor
- Tanabe Pharma Corporation
Chronic Kidney Disease, Diabetic Nephropathy
Evaluate the Efficacy and Safety of Once Daily Administration of Atrasentan Tablets (Low and High) Compared to Placebo in Reducing Residual Albuminuria in Type 2 Diabetic Patients With Nephropathy Who Are Treated With the Maximum Tolerated Labeled Dose of a Renin Angiotensin System (RAS) Inhibitor
Prospective, Randomized, Double-Blind, Placebo-Controlled Multicenter Study. The objective of the study is to evaluate the efficacy and safety of once daily administration of atrasentan tablets (low dose and high dose) compared…
- Trial name
- RADAR (NCT01356849)
- Testing
- Atrasentan
- Where
- 72 sites in United States, Canada and 2 more
- Volunteers
- 149 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Diabetic Nephropathy, Diabetic Kidney Disease
Pyridorin in Diabetic Nephropathy
The purpose of this study is to evaluate the safety and efficacy of oral Pyridorin 300 mg BID in reducing the rate of progression of nephropathy due to type 2 diabetes mellitus.
- Trial name
- PIONEER (NCT02156843)
- Testing
- Pyridorin
- Where
- 137 sites in United States, Australia and 10 more
- Volunteers
- 328 people
- Sponsor
- NephroGenex, Inc.